Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 151


α1-blocker tamsulosin as initial treatment for patients with benign prostatic hyperplasia: 5-year outcome analysis of a prospective multicenter study.

Masumori N, Tsukamoto T, Horita H, Sunaoshi K, Tanaka Y, Takeyama K, Sato E, Miyao N.

Int J Urol. 2013 Apr;20(4):421-8. doi: 10.1111/j.1442-2042.2012.03165.x. Epub 2012 Sep 19.


Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe.

Chapple CR, Montorsi F, Tammela TL, Wirth M, Koldewijn E, Fernández Fernández E; European Silodosin Study Group..

Eur Urol. 2011 Mar;59(3):342-52. doi: 10.1016/j.eururo.2010.10.046. Epub 2010 Nov 10.


Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension.

Drake MJ, Chapple C, Sokol R, Oelke M, Traudtner K, Klaver M, Drogendijk T, Van Kerrebroeck P; NEPTUNE Study Group..

Eur Urol. 2015 Feb;67(2):262-70. doi: 10.1016/j.eururo.2014.07.013. Epub 2014 Jul 25.


The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.

Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Nandy I, Morrill BB, Gagnier RP, Montorsi F; CombAT Study Group..

Eur Urol. 2010 Jan;57(1):123-31. doi: 10.1016/j.eururo.2009.09.035. Epub 2009 Sep 19. Erratum in: Eur Urol. 2010 Nov;58(5):801.


Effects of three types of alpha-1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia.

Yokoyama T, Hara R, Fukumoto K, Fujii T, Jo Y, Miyaji Y, Nagai A, Sone A.

Int J Urol. 2011 Mar;18(3):225-30. doi: 10.1111/j.1442-2042.2010.02708.x. Epub 2011 Jan 27.


The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study.

Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Morrill B, Montorsi F; CombAT Study Group..

J Urol. 2008 Feb;179(2):616-21; discussion 621. Epub 2007 Dec 21. Erratum in: J Urol. 2008 Sep;180(3):1191.


Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.

Emberton M, Lukacs B, Matzkin H, Alcaraz A, Elhilali M, Vallancien G.

J Urol. 2006 Sep;176(3):1051-6.


Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.

Roehrborn CG, Kaplan SA, Kraus SR, Wang JT, Bavendam T, Guan Z.

Urology. 2008 Nov;72(5):1061-7; discussion 1067. doi: 10.1016/j.urology.2008.06.067. Epub 2008 Sep 25.


Comparison of the response to treatment between Asian and Caucasian men with benign prostatic hyperplasia: long-term results from the combination of dutasteride and tamsulosin study.

Chung BH, Lee SH, Roehrborn CG, Siami PF, Major-Walker K, Wilson TH, Montorsi F; CombAT Study Group..

Int J Urol. 2012 Nov;19(11):1031-5. doi: 10.1111/j.1442-2042.2012.03091.x. Epub 2012 Jul 9.


A randomized controlled study of the efficacy of tamsulosin monotherapy and its combination with mirabegron for overactive bladder induced by benign prostatic obstruction.

Ichihara K, Masumori N, Fukuta F, Tsukamoto T, Iwasawa A, Tanaka Y.

J Urol. 2015 Mar;193(3):921-6. doi: 10.1016/j.juro.2014.09.091. Epub 2014 Sep 22.


Does sildenafil enhance the effect of tamsulosin in relieving acute urinary retention?

Sharifi SH, Mokarrar MH, Khaledi F, Yamini-Sharif R, Lashay A, Soltani MH.

Int Braz J Urol. 2014 May-Jun;40(3):373-8. doi: 10.1590/S1677-5538.IBJU.2014.03.11.

Supplemental Content

Support Center